Unmet need in heavily pre-treated patients with HR+/HER2-metastatic breast cancer (mBC) in the US: A ConcertAI analysis

被引：1
|
作者：
Waks, A. G. [1 ]
Gharaibeh, M. [2 ]
Sjekloca, N. [3 ]
Poluparthi, N. [2 ]
Shah, A. [2 ]
Bergamaco, E. [4 ]
MacCannell, T. [2 ]
Leung, G. [5 ]
Ntalla, I. [6 ]
Oko-osi, H. [2 ]
Tolaney, S. M. [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Gilead Sci Inc, Dept Hlth Econ & Outcomes Res, Foster City, CA USA
[3] Gilead Sci Europe Ltd, Dept Med Affairs, Stockley Pk, CA USA
[4] Gilead Sci Inc, Dept Med Affairs, Foster City, CA USA
[5] Gilead Sci Inc, Dept Real World Evidence, Foster City, CA USA
[6] Gilead Sci Europe Ltd, Dept Real World Evidence, Stockley Pk, CA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253P
引用
收藏
页码：S653 / S653
页数：1
相关论文
共 50 条
  • [31] Everolimus in heavily pre-treated metastatic breast cancer (MBC): Is real (developing) world experience different?
    Bajpai, J.
    Ramaswamy, A.
    Ghosh, J.
    Gulia, S.
    Gupta, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S292 - S292
  • [32] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer
    Huober, J.
    Hamilton, E.
    Cortes, J.
    Ozyilkan, O.
    Chen, S. C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Chapman, S.
    Yang, Z.
    Chen, Y.
    Johnston, E.
    Martin, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 244 - 245
  • [33] Safety profile and activity of lower capecitabine dose in chemionaive and heavily pre-treated patients with metastatic breast cancer (MBC)
    Rossi, D.
    Alessandroni, P.
    Catalano, V
    Giordani, P.
    Baldelli, A. M.
    Luzi, Fedeli S.
    Fedeli, A.
    Casadei, V
    Ceccolini, M.
    Tamburrano, T.
    Catalano, G.
    ANNALS OF ONCOLOGY, 2006, 17 : XI11 - XI11
  • [34] Increased survival for heavily pre-treated metastatic breast cancer
    Siddall, Rhonda
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 370 - 370
  • [35] TREATMENT WITH ERIBULIN (HALAVEN) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC BREAST CANCER
    Lynge, M.
    Liposits, G. I.
    Linnet, S.
    Langkjer, S. T.
    BREAST, 2013, 22 : S43 - S43
  • [36] Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer
    Rasmussen, Maja Lynge
    Liposits, Gabor
    Yogendram, Subethini
    Jensen, Anders Bonde
    Linnet, Soren
    Langkjer, Sven Tyge
    ACTA ONCOLOGICA, 2014, 53 (09) : 1275 - +
  • [37] Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2-metastatic breast cancer (mBC) in the US
    Park, Leah
    Thompson, Samantha L.
    Roose, James
    Lu, Yichen
    Chaki, Moumita
    Lam, Clara
    Iorgulescu, Bryan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [39] HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY
    Collin, S.
    Tse, J.
    Shaikh, N. F.
    Near, A.
    Hamilton, E.
    Brufsky, A.
    Gradishar, W.
    Mehta, S.
    Long, G. H.
    Toms, N.
    VALUE IN HEALTH, 2024, 27 (06) : S134 - S134
  • [40] A LONGITUDINAL INVESTIGATION OF THE RELATIONSHIPS BETWEEN PATIENT REPORTED SYMPTOMS AND SURVIVAL AMONG PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) TREATED WITH ABEMACICLIB IN THE PHASE 2 MONARCH 1 TRIAL
    Houghton, K.
    Boye, M. E.
    Price, G. L.
    Stull, D. E.
    Tolaney, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A413 - A413
12345